• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K/A filed by AnPac Bio-Medical Science Co. Ltd. (Amendment)

    12/1/23 9:43:05 PM ET
    $ANPC
    Medical Specialities
    Health Care
    Get the next $ANPC alert in real time by email

     

     

    U.S. SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K/A

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2023

     

    Commission File Number: 001-39137

     

    Fresh2 Group Limited

     

    650 5TH AVE STE 2416

    NEW YORK, NY 10019-6108

    United States

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F  ☒     Form 40-F  ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Form 6-K/A is being filed as an amendment to the Form 6-K dated November 9, 2023 (the “Original Form 6-K”). The purpose of this Form 6-K/A is to amend Exhibits 99.1 and 99.2 of the Original Form 6-K. The amendments made in this document are as follows:

     

      ● Numerical and Wording Revisions: We have made necessary corrections to certain numerical data and wording to ensure accuracy and clarity. These revisions do not materially alter the financial condition or results of operations previously reported.
           
        1. We corrected disclosures regarding loss from disposal of Changwei on page F-18.
           
        2. We corrected disclosures regarding revenues from related parties and third parties for the six months ended June 30, 2023 on page F-18.
           
        3. We corrected disclosures regarding B. Liquidity and Capital Resources on page 5:
           
          1) we changed the working capital deficit as of June 30, 2023 from RMB32,482 million to RMB32.5 million;
             
          2) we changed the value of convertible notes from US$2,000 million to US$2 million;
             
          3) we changed the two tranches of convertible notes sold from US$400 and US$1,600 to US$400,000 and US$1,600,000, respectively;
             
          4) we changed the first payment received from RMB1,697 (US$234) to RMB1,697,000 (US$234,000).
             
        4. We corrected the disclosures regarding capital expenditures for the six months ended June 30, 2022 and 2023 on page 6.

     

    ●Additional Disclosures:

     

      1. We added and corrected disclosures regarding the GISN acquisition on page F-16 and page F-32, specific changes were made to 1) correct the disclosure to note the GISN acquisition is not from a related party, 2) correct the fair value of the assets acquired and liabilities assumed table to include ROU which was missed previously and added the omitted disclosure about revenue contributed by GISN for the six months ended June 30, 2023.

     

    2.We added Information pertaining to recent dispositions to provide a more comprehensive understanding of our financial activities.

     

    ●Accounting Policy Modifications: Changes have been made to reflect updates in accounting policy after the adoption of ASU 2017-04 in 2022 on page F-9.

     

    ●Revision of Product Warranty and Return Policy Description: We have updated the descriptions of our product warranty and return policy to better reflect current practices and ensure transparency on page F-12.

     

    Except as described herein, no other changes have been made to the Original Form 6-K.

     

    1

     

     

    EXHIBIT INDEX

     

    Exhibit   Description
    99.1   Unaudited Condensed Consolidated Financial Statements as of June 30, 2023
    99.2   Management’s Discussion and Analysis of Results of Operations
    101.INS   Inline XBRL Instance Document
    101.SCH   Inline XBRL Taxonomy Extension Schema Document
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

      Fresh2 Group Limited
       
      By: /s/ Haohan Xu
      Name:  Haohan Xu
      Title: Chief Executive Officer
         
    Dated: December 1, 2023    

     

     

    3

     

     

    Get the next $ANPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANPC
    Leadership Updates

    Live Leadership Updates

    See more
    • AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

      PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of directors appointed Jiawen Kang as a member of the board of directors of the Company (the "Board") and a member of the Audit Committee and Nominating Committee. On that date, the Company also appointed Yuyang Cui as (a) Co-Chairman of the Board and (b) Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presentin

      8/5/22 4:45:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees

      PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members (the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member's resolution

      7/18/22 6:39:14 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member

      PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replace

      4/8/22 9:12:52 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Financials

    Live finance-specific insights

    See more
    • AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider

      NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer

      2/15/23 8:00:00 AM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

      Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra

      5/19/23 12:55:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela

      5/16/23 5:00:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Reports Fiscal Year 2022 Annual Financial Results

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021.  Gross margi

      5/16/23 4:15:00 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    SEC Filings

    See more

    $ANPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ANPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/16/24 4:36:43 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/1/24 4:01:33 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      1/29/24 5:29:36 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Liang Zhijun

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:31:07 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Zhao Zhigang

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:29:59 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Li Xiaoyu

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:28:09 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13D filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13D - Fresh2 Group Ltd (0001786511) (Subject)

      7/27/23 4:10:19 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      3/24/23 6:09:00 AM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by AnPac Bio-Medical Science Co. Ltd. (Amendment)

      SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      10/12/22 4:45:23 PM ET
      $ANPC
      Medical Specialities
      Health Care